熱門詞： 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥
ChinaBio ChinaBio
ChinaBio? 的故事始于一次旅行... 2006年11月，我們的創始人Greg Scott先生第一次到訪中國。他為赴一次商務會面來到了上海張江高科技園。這次會議后，他簡要走訪了這個占地面積
因此2007年1月下旬，他再次來到中國，計劃停留一周時間，只安排了2場會議。但到這周結束時他已經進行了30多次會議，他心里已經播下了ChinaBio? 的種子。到了4月，ChinaBio? 在張江高科技園區藥谷大廈開設了辦公室，招進了第一位員工。當時他常聽說鮮有人對中國的早期生物技術/醫藥技術感興趣，而他就成了這少數人之一，并且在與數家極具發展潛力的公司合作之后，他更是熱情高漲。
世界發現中國生物技術
2007年8月，無錫姚明康德上市了，緊隨其后的是其他幾家中國生物技術企業的首次公開募股。整個世界突然意識到中國也有生物技術產業，并想了解更多，然后開始紛紛涌至中國。2008年初，我們搬到了對面更大的辦公室，公司團隊也從2名擴大到10名全職和數名兼職員工。Scott先生還接受了中央電視臺英文國際頻道及幾家電臺和互聯網節目的采訪。
到2010年底， ChinaBio? 已經在中國舉辦了的15次重大會議，包括10次ChinaBio?創業投資論壇和兩屆ChinaBio?合作論壇，并在舊金山和布魯塞爾舉辦參會人數近4000人的“中國節”活動。2011年我們計劃主辦5次主要會議，包括我們的首屆ChinaBio? 領導人高爾夫年會。（詳情參見“會議預告”欄目）
我們與一些包括羅氏、輝瑞及Life Technologies在內的全球最具影響力的醫藥和生物技術公司進行了合作，幫助中國生物醫藥公司融資逾4億美元。我們的公司內部調研團隊密切追蹤中國生物技術行業的商業動態，包括新技術研發、臨床實驗活動、風險投資、并購及首募活動等。這些信息幫助我們和我們的客戶深入了解行業發展動向并準確預測中國對未來全球生物醫藥產業的影響。
Scott先生已經是以上海為家，樂享中國的無限活力而放棄圣地亞哥的陽光和沙灘。中國的事務發展之快仍讓他驚喜不已。
It Begins with a Vacation
The story of ChinaBio? starts with a vacation... In November 2006, our founder, Greg Scott, visited China for the first time. He had arranged to have one business meeting while he was in Shanghai at Zhangjiang Hi-Tech Park. From that single meeting, and a brief tour of the 25 sq. km Park where he saw Roche, Pfizer, GSK, Lilly, and over 200 early-stage biotech companies, he knew he would be coming back to China. His 10-years of experience as an angel investor in biotech in the US led him to believe that there was something "big" happening in China, and he had to find out more.
So in late January 2007, he returned for one week with only two scheduled meetings. By the end of the week and over 30 meetings, the seeds of ChinaBio? were sown. By April, ChinaBio's offices were open in the Biotech VC Plaza building in Zhangjiang Hi-Tech Park, and the first staff was hired. While often told he was one of the very few interested in early-stage biotech/medtech in China, his interest remained high as he worked with several promising companies.
The World Discovers China Biotech
Then, in August 2007, WuXi PharmaTech went public, quickly followed by several other China biotech IPOs. Suddenly the world knew there was a biotech industry in China and wanted to know more and began beating a path to ChinaBio's door. By early 2008, ChinaBio had moved to larger offices and expanded the staff from two to six full time and three part time members. Mr. Scott had also been interviewed on CCTV and several radio and internet shows.
By the end of 2010, ChinaBio? had organized over 15 major conferences in China, including 10 ChinaBio? Investor Forums, two ChinaBio? Partnering Forums, and China Day events in San Francisco and Brussels, hosting a combined total of nearly 4000 attendees. For 2011, ChinaBio is planning five major events, including our new ChinaBio?Leadership Retreat. (See .)
ChinaBio? has also worked with some of the world's most respected life science companies, including Pfizer, Roche Diagnostics and Life Technologies, and helped China biomedical companies raise over $400M US. Our in-house research team tracks China's biotech industry including novel technology development, clinical trial activity, VC investments, IPOs and M&A and partnering activity. This information gives us and our clients critical insights into the direction of the industry and how China will impact the future of the global biopharma industry.
Mr. Scott now makes Shanghai his home, trading the sunshine and beaches of San Diego for the vitality of China. It surprises even him how quickly things can move in China.
知識產權侵權投訴：不生產任何產品所有產品均來自產品的生產廠商、代理商、經銷商，如有侵權請聯系：400-006-7520 ，我們會在第一時間處理
本網站所有產品與藥品無關
滬公網安備31011502016460號
